American Society of Hematology

SHERPA: Blue

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Hamlin
    Hamlin
  7. Kumar
    Kumar
  8. Salles
    Salles
  9. Yahalom
    Yahalom
  10. Dogan
    Dogan

Groups

  1. Center for Hematologic Malignancies (898)
  2. Department of Medicine (898)
  3. Hematologic Malignancies, Division of (898)
  4. Lymphoma (898)
  5. Population Sciences Research Program (271)
  6. Survivorship Research (229)
  7. Epidemiology and Biostatistics (143)
  8. Executive Committee, Center for Hematologic Malignancies (126)
  9. GSK Faculty (121)
  10. Biostatistics Service (118)
Search Within
  1. "Lymphoma"
Formats
  1. Meeting Abstract (722)
  2. Journal Article (150)
  3. Review (9)
  4. Research Letter (8)
  5. Editorial (5)
  6. Guidelines (3)
  7. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (898)
  2. Department of Medicine (898)
  3. Hematologic Malignancies, Division of (898)
  4. Lymphoma (898)
  5. Population Sciences Research Program (271)
  6. Survivorship Research (229)

More Groups

People
  1. Andrew Zelenetz (328)
  2. Steven Horwitz (258)
  3. Maria Palomba (183)
  4. Ariela Noy (163)
  5. Alison Moskowitz (154)
  6. Craig Moskowitz (128)

More People

Years
  1. 2025 (5)
  2. 2024 (30)
  3. 2023 (87)
  4. 2022 (61)
  5. 2021 (66)
  6. 2020 (52)

More Years

Publications
  1. Blood (833)
  2. Blood Advances (56)
  3. Hematology-American Society of Hematology Education Program (9)

Results (898)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Extended use of rituximab in older adults with non-Hodgkin lymphoma
    Meeting Abstract

    Matasar, M. J.; Atoria, C. L.; Elkin, E. B.; Nabhan, C.
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or Sezary syndrome: Final results show significant clinical activity and suggest correlation with CD30 expression
    Meeting Abstract

    Kim, Y. H.; Tavallaee, M.; Rozati, S.; Sundram, U.; Salva, K.; Wood, G. S.; Li, S.; Krathen, M.; Nagpal, S.; Reddy, S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic profiling combining DNA and RNA analysis of 112 formalin-fixed paraffin-embedded diffuse large B cell lymphoma specimens identifies a high frequency of clinically relevant genomic alterations
    Meeting Abstract

    Intlekofer, A. M.; Hilden, P.; Seshan, V. E.; Copeland, A. R.; Levine, R. L.; Zelenetz, A. D.; Teruya-Feldstein, J.; Dogan, A.; Palomba, M. L.; Moskowitz, C. H.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Leukemia-associated oncometabolite 2-hydroxyglutarate regulates epigenetic modifications in response to oxygen availability in cells without IDH1/2 mutations
    Meeting Abstract

    Intlekofer, A. M.; DeMatteo, R. G.; Finley, L. W.; Cross, J. R.; Thompson, C. B.
    Blood (2014)

    Fulltext@MSK | Save
  • Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Porcu, P.; Flinn, I.; Kahl, B. S.; Sweeney, J.; Stern, H. M.; Douglas, M.; Allen, K.; Kelly, P.; Foss, F. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Clinical utility of comprehensive profiling of genomic alterations in hematologic malignancies
    Meeting Abstract

    He, J.; Bufill, J. A.; Nahas, M. K.; Wang, K.; Young, L. E.; Knapp, K. M.; Brennan, K. W.; Donahue, A. L.; Young, G.; Ross, J. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic analysis of serial samples from CLL patients identifies clonal events associated with disease progression
    Meeting Abstract

    Gardner, J. R.; Nahas, M.; He, J.; Aumann, S.; Gonen, M.; Patel, M.; Knapp, K. M.; Palomba, M. L.; Yelensky, R.; Donahue, A. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save